{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 447923576
| IUPAC_name = 4-(aminocarbonyl)-1-[((6''R'',7''R'')-2-carboxy-8-oxo-7-{[phenyl(sulfo)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]pyridinium
| image = cefsulodin.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|cefsulodin}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 52152-93-9
| ATC_prefix = J01
| ATC_suffix = DD03
| PubChem = 5284530
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4447588
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = OV42LHE42B
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02005
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1617285

<!--Chemical data-->
| C=22 | H=21 | N=4 | O=8 | S=2 | charge = + 
| molecular_weight = 533.556 g/mol
| smiles = O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(c3ccccc3)S(=O)(=O)O)C[n+]4ccc(C(=O)N)cc4)C([O-])=O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)/t15-,17?,21-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SYLKGLMBLAAGSC-IKZMBGHXSA-N
}}

'''Cefsulodin''' is a third-generation [[cephalosporin]] antibiotic that is active against ''[[Pseudomonas aeruginosa]]'' and was discovered by [[Takeda Pharmaceutical Company]] in 1977.<ref name="racgp">[https://web.archive.org/web/20110927174740/https://www.toku-e.com/Upload/Products/Article/20110323002554.pdf TOKU-E Technical Application Sheet]</ref>

[[TAP Pharmaceuticals]] had a new drug application on file with FDA for cefsulodin under the brand name Cefonomil as of 1985.<ref>{{cite news|title=Lupron Is First Abbott-Takeda Product to Reach U.S. Market|url=https://pink.pharmamedtechbi.com/PS008170/LUPRON-IS-FIRST-ABBOTTTAKEDA-PRODUCT-TO-REACH-US-MARKET-FDA-APPROVES-SYNTHETIC-LHRH-ANALOG-WAS-TREATED-AS-1A-BREAKTHROUGH-FOR-PROSTATE-CANCER|work=Pink Sheet|date=15 April 1985}}</ref>

Cefuslodin is most commonly used in cefsulodin-irgasan-novobiocin agar to select for ''Yersinia'' microorganisms.<ref>{{cite web|title=BAM Media M35: Cefsulodin-Irgasan Novobiocin Agar or Yersinia Selective Agar|url=http://www.fda.gov/Food/ScienceResearch/LaboratoryMethods/BacteriologicalAnalyticalManualBAM/ucm064575.htm|accessdate=2 September 2012}}</ref> This agar is most often used in water and beverage testing.

== Susceptibility data ==
The following represents MIC susceptibility data for various ''P. aeruginosa'' strains:<ref>http://antibiotics.toku-e.com/antimicrobial_474.html</ref>
* ''Pseudomonas aeruginosa'' PA13 (resistant strain): 32 μg/ml
* ''Pseudomonas aeruginosa'' (wild-type, susceptible): 4 - 8 μg/ml

==References==
{{Reflist}}

{{CephalosporinAntiBiotics}}

[[Category:Cephalosporin antibiotics]]
[[Category:Isonicotinamides]]
[[Category:Takeda Pharmaceutical Company]]